People with diffuse cutaneous systemic sclerosis (dcSSc) treated with lenabasum keep improving after 21 months of treatment, results from…
Articles by Patricia Inácio, PhD
Targeting a signaling molecule called CCL24 with a new antibody was seen to lessen inflammation and scarring (fibrosis) in a…
Combined pulmonary fibrosis and emphysema (CPFE) impairs lung function and decreases survival rates of systemic sclerosis (SSc) patients, a retrospective…
Men older than 50 with diffuse cutaneous systemic sclerosis (dcSSc) have higher levels of estradiol, an active form of…
A simple routine blood test that measures the levels of immune cells called monocytes may help identify patients with fibrotic…
The enzyme EZH2 is present in higher-than-normal levels in fibroblasts and endothelial cells from scleroderma patients, a study shows, and…
Inhibiting the protein PU.1 has potential as a therapy to treat multiple fibrotic diseases, including systemic sclerosis, a new…
Treatment with rituximab may help improve the clinical symptoms of calcinosis — the formation of calcium deposits in the skin and muscle…
Treatment with rituximab appears to stabilize microcirculation — blood circulation in small vessels called capillaries — in patients with long-term…
Autoantibodies against fat molecules present in the membrane of cells, called antiphospholipid antibodies, are associated with an increased risk of…